2024年5月29日 · M9140 is the first anti-CEACAM5 ADC with a topoisomerase 1 inhibitor (Top1i) payload (exatecan). The ß-glucuronide linker connecting the M9140 antibody backbone to the …

2024年3月22日 · The TOP1 inhibitor-based ADC M9140 caused strong antitumor efficacy with a tumor volume reduction of 74% and 88% as best response in two CRC PDX models where a …

2022年4月1日 · Tusamitamab ravtansine plasma concentrations were determined using a validated immunoassay detecting the ADC bearing at least one DM4 molecule. PK parameters …

2020年12月15日 · Here, we describe preclinical data for a novel antibody-drug conjugate (ADC), SAR408701, which consists of an anti-CEACAM5 antibody (SAR408377) coupled to a …

Conclusions: Tusamitamab ravtansine had a favorable safety profile with reversible, dose-related keratopathy as the DLT. Based on the overall safety profile, pharmacokinetic data, and …

2022年1月10日 · Both DM4 and S-methyl-DM4 can cross the membrane and lead to a target-enhanced ‘bystander effect’ in which cytotoxicity can be seen in both target-expressing

M9140 is an anti-CEACAM5 ADC that selectively delivers a cytotoxic topoisomerase 1 inhibitor payload (exatecan). Preliminary data from the dose escalation part of the ongoing trial …

study. Conclusions: M9140 demonstrated encouraging activity in heavily pretreated pts with advanced CRC, with a manageable and predictable safety profile. Contrary to approved ADCs …

2024年6月11日 · 今年的ASCO会议上公布了M9140在人体进行的一期临床试验结果，来自美国、欧盟和日本的40名晚期结直肠癌患者接受了7个剂量的药物治疗，这些患者之前都用了标准治 …

2024年5月17日 · m9140是默克使用专有技术开发的一种抗体药物偶联物（adc），靶向表达癌胚抗原相关细胞粘附分子5 （ceacam5）的癌细胞。 默克的ADC管线以靶向CEACAM5 M9140为 …